Biodegradable Polymer Microspheres with Natural Cross-Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biodegradable polymers for therapeutic embolization face issues such as sensitivities, catheter clogging, slow drug release, and complex safety evaluations, particularly with synthetic polymers like polyesters and PVA cross-linked with non-natural cross-linkers.
Innovation Solution
Development of polyhydroxylated polymers cross-linked with naturally occurring C4 or C5 alpha keto acids, such as PVA with alpha-ketoglutarate, allowing for tunable degradation and incorporation of drugs, radiopaque agents, and biocompatibility, with methods for forming microspheres.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If synthetic biodegradable polymers like polyesters are used, then drug incorporation is enabled, but catheter clogging occurs due to poor compressibility
Solution Approach 1:
The patent changes the physical parameters of the polymer by using polyvinyl alcohol instead of traditional polyesters, creating a hydrophilic polymer that forms compressible microspheres. This parameter change enables both drug incorporation and smooth catheter delivery without clogging, resolving the contradiction between drug loading capability and ease of delivery.
Solution Approach 2:
The patent creates a composite microsphere system combining polyvinyl alcohol with cross-linking agents and drug substances. This composite structure allows the polymer to maintain compressibility for catheter delivery while providing pathways for drug incorporation and release, simultaneously addressing both requirements.
2Stability of the object's composition
If PVA is cross-linked with non-natural cross-linkers, then structural stability is improved, but safety and clearance become complex
Solution Approach 1:
The patent changes the chemical parameter of the cross-linker from non-natural to natural alpha-keto acids (such as alpha-ketoglutarate). This parameter change maintains the structural stability needed for microsphere integrity while ensuring biocompatibility and clear metabolic pathways, simplifying safety evaluation and clearance.
Solution Approach 2:
The patent employs naturally occurring cross-linkers that are metabolically active and temporarily present in the body, breaking down into safe products. This approach treats the cross-linking structure as a temporary, biocompatible element that fulfills its structural role and then naturally degrades, eliminating long-term safety concerns.
3Reliability
If polyhydroxylated polymers are used, then biocompatibility is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent changes the polymer chemistry parameter to polyvinyl alcohol, a well-established material with known manufacturing processes. By adjusting parameters such as molecular weight and hydroxyl content, the patent achieves enhanced biocompatibility while maintaining existing manufacturing capabilities, avoiding the need for entirely new production processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymers provide rapid clearance from the body, controlled drug release, reduced catheter clogging, and enhanced imaging capabilities, while ensuring safety and efficacy in therapeutic embolization procedures.
Implementation Method 1
a polymer having a backbone comprising a polyhydroxylated polymer the polyhydroxylated polymer cross-linked by a C4 or C5 diacid selected from a C4 or C5 alpha keto acid
Implementation Method 2
The polymers provide rapid clearance from the body, controlled drug release
Data Source
Figure 1
Figure 2A~2C
Figure 3
AI summary
A polymer having a backbone comprising a polyhydroxylated polymer cross linked by a C3 to C8 diacid.